Effect of combination of a tissue-type plasminogen activator and an endothelin receptor antagonist, FR139317, in the rat cerebral infarction model

By Umemura K.   Ishiye M.   Kosuge K.   Nakashima M.  

European Journal of Pharmacology, Vol. 275, Iss. 1, 1995-02 ,pp. : 17-21

Elsevier

Access to resources Recommend Favorite

Pharmacology of A-216546: a highly selective antagonist for endothelin ET A receptor

By Wu-Wong J.R.   Dixon D.B.   Chiou W.J.   Dayton B.D.   Novosad E.I.   Adler A.L.   Wessale J.L.   Calzadilla S.V.   Hernandez L.   Marsh K.C.   Liu G.   Szczepankiewicz B.   von Geldern T.W.   Opgenorth T.J.  

European Journal of Pharmacology, Vol. 366, Iss. 2, 1999-02 ,pp. : 189-201

Elsevier

Access to resources Recommend Favorite

Early administration of YT-146, an adenosine A 2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury

By Takiguchi Y.   Nagano M.   Ikeda Y.   Nakashima M.  

European Journal of Pharmacology, Vol. 281, Iss. 2, 1995-08 ,pp. : 205-207

Elsevier

Access to resources Recommend Favorite

An orally active non-selective endothelin receptor antagonist, bosentan, markedly reduces injury in a rat model of colitis

By Hogaboam C.M.   Muller M.J.   Collins S.M.   Hunt R.H.  

European Journal of Pharmacology, Vol. 309, Iss. 3, 1996-08 ,pp. : 261-269

Elsevier

Access to resources Recommend Favorite

Determination of an endothelin receptor antagonist in rat plasma by radioimmunoassay

By Yuan S.   Cylc D.   Hsieh J.Y.-K.   Matuszewski B.K.  

Journal of Pharmaceutical and Biomedical Analysis, Vol. 34, Iss. 2, 2004-02 ,pp. : 391-397

Elsevier

Access to resources Recommend Favorite